Lucira was one of several diagnostic companies that rose to prominence during the pandemic. In November 2020, the California-based company received the first FDA authorization for a fully at-home COVID-19 test. Early the following year, Lucira raised $176 million through an initial public offering. As demand for COVID-19 tests waned in 2022, the company worked to get a flu combination test to market by the fall of last year.
